People · Operator
Named in public records as an officer, director or promoter · active 2013–2022 · Biotechnology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Delfi Diagnostics, Inc. | — | Biotechnology | Series D+ | $365.9M | $235.9M | 2022 |
| Aravive, Inc. | — | Biotechnology | Series C | $156.1M | $702.9M | 2013 |
| Levo Therapeutics, Inc. | — | Pharma | Series C | $86.5M | $1.4B | 2017 |
| Principia Biopharma Inc. | — | Biotechnology | Series C | $77.4M | $2.0B | 2015 |
| Nkarta, Inc. | — | Biotechnology | Series C | $43.9M | $1.8B | 2019 |
MICHAEL DYBBS at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside MICHAEL DYBBS on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Srinivas Akkaraju | 2 | 10 |
| Ali Behbahani | 1 | 17 |
| Peter Thompson | 1 | 16 |
| Rishi Gupta | 1 | 12 |
| Kevin Johnson | 1 | 12 |
| Tiba Aynechi | 1 | 9 |
| Fouad Azzam | 1 | 8 |
| Greg Yap | 1 | 8 |
| Anthony Sun | 1 | 8 |
| Simeon George | 1 | 8 |
| Alan Colowick | 1 | 7 |
| Daniel Becker | 1 | 5 |
| Jill Carroll | 1 | 4 |
| Shahzad Malik | 1 | 4 |
| Nassim Usman | 1 | 4 |
| JEFFREY CLELAND | 1 | 4 |
| Michael W. Rogers | 1 | 4 |
| Francesco De Rubertis | 1 | 4 |
| Lewis J. Shuster | 1 | 4 |
| Justin Kao | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.